IP Library Granted Patent US 9,919,077
Granted Patent B2
US 9,919,077 · App. 14/897,352 · Granted Mar 20, 2018

Co-precipitation of a therapeutic agent into hydroxyapatite coatings

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,919,077
App. No.
14/897,352
Granted
Mar 20, 2018
Kind
B2
Abstract

A method for co-precipitating a therapeutic agent into a hydroxyapatite coated surface includes the steps of providing a surface and applying a hydroxyapatite seed layer on the surface. The hydroxyapatite seed layered surface is contacted with a solution including the therapeutic agent and a co-precipitated therapeutic agent, hydroxyapatite layer is formed on the coated surface to uniformly distribute the therapeutic agent in the layer. Further, an implant having sustained therapeutic agent delivery includes a base and an hydroxyapatite seed layer disposed on a surface of the base. A co-precipitated hydroxyapatite coating is disposed on the seed layer. The coating includes a therapeutic agent, wherein the therapeutic agent is provided in a solution of therapeutic agent.

Claims (22)

1. A method for co-precipitating a therapeutic agent into a hydroxyapatite coated surface comprising the steps of:

providing a surface which includes a coating selected from the group of TiO 2 , TiO, TiCrO 2 , Ti 2 O 3 , Ti 3 O 5 , SiO 2 , MgO 2 , AlO 2 , MgO, Al 2 O 3 , and CrO 2 ;

applying a hydroxyapatite seed layer having a thickness of 0.1 μm to 1 μm on the surface;

contacting the hydroxyapatite seed layered surface with a solution including the therapeutic agent; and

forming a co-precipitated therapeutic agent, hydroxyapatite layer on the coated surface to uniformly distribute the therapeutic agent in the layer.

2. A method according to claim 1 , wherein the therapeutic agent is selected from the group of antibiotics, vitamins, chemotherapy drugs, bisphosphonates, strontium ranelate, PTH, osteoporotic drugs, growth factors, or a combination thereof.

3. A method according to claim 1 , wherein the surface is a material selected from the group of titanium, titanium alloy, nickel-titanium alloy, tantalum, platinum-iridium alloy, gold, magnesium, stainless steel, chromo-cobalt alloy, ceramics, biocompatible plastics or polymers and combinations thereof.

4. A method according to claim 1 , wherein the hydroxyapatite seed layer is grown biomimetically.

5. A method according to claim 1 , wherein the co-precipitated therapeutic agent, hydroxyapatite layer is grown biomimetically.

6. A method according to claim 1 , wherein the thickness of the co-precipitated layer is of 1 μm to 10 μm.

7. A method according to claim 1 , wherein the therapeutic agent in the solution including the therapeutic agent has a concentration of 0.5 to 40 mg/ml.

8. A method according to claim 1 , wherein the co-precipitated therapeutic agent, hydroxyapatite layer and the seed layer are ion substituted hydroxyapatite.

9. A method according to claim 8 , wherein the substitution ions are bone mineral relevant ions.

10. A method according to claim 8 , wherein the substitution ions are selected from the group of Si, Sr, Mg, C02-3, and F ions.

11. A method according to claim 1 , wherein the solution including the therapeutic agent is heated to a temperature of about 30° C. to about 90° C.

12. A method according to claim 11 , wherein the temperature is 60° C.

13. A method according to claim 1 , wherein the seed layer is applied by soaking the surface in phosphate buffered saline solution containing calcium and phosphate ions.

14. A method according to claim 13 , wherein the phosphate buffered saline solution has a temperature of from 30 to 90° C.

15. A method according to claim 14 , wherein the phosphate buffered saline solution has a temperature of 60° C.

16. A hydroxyapatite coated surface co-precipitated with a therapeutic agent according to the method of claim 1 .

17. A device having a hydroxyapatite coated surface co-precipitated with a therapeutic agent according to the method of claim 1 .

18. The device of claim 17 , wherein the device is selected from the group of implants, pins, fixation pins, orthopedic devices, dental implants, stents, drug delivery devices, sheets, films, meshes, soft tissue implants, implantable electrodes, implantable sensors, drug delivery pumps, tissue barriers and shunts.

Assignments (8)
CHANGE OF ADDRESS Recorded Dec 18, 2024
From: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
To: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
Reel/Frame 069730/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2023
From: STRYKER TRAUMA GMBH
To: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
Reel/Frame 064493/0058 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 23, 2021
From: STRYKER EUROPEAN HOLDINGS I, LLC
To: STRYKER EUROPEAN HOLDINGS III, LLC
Reel/Frame 056969/0771 →
CHANGE OF NAME Recorded Jul 23, 2021
From: STRYKER EUROPEAN HOLDINGS III, LLC
To: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
Reel/Frame 056969/0893 →
NUNC PRO TUNC ASSIGNMENT Recorded Dec 6, 2017
From: STRYKER EUROPEAN HOLDINGS VI, LLC
To: STRYKER EUROPEAN HOLDINGS I, LLC
Reel/Frame 044717/0440 →
NUNC PRO TUNC ASSIGNMENT Recorded Dec 4, 2017
From: STRYKER TRAUMA GMBH
To: STRYKER EUROPEAN HOLDINGS VI, LLC
Reel/Frame 044782/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2017
From: STRYKER TRAUMA GMBH
To: STRYKER EUROPEAN HOLDINGS I, LLC
Reel/Frame 044275/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2017
From: LILJA, MIRJAM; PROCTER, PHILIP; STECKEL, HARTWIG; SÖRENSEN, TORBEN CHRISTIAN; SÖRENSEN, JAN HENRIK
To: STRYKER TRAUMA GMBH
Reel/Frame 044251/0318 →